Hemoconcentration-guided Diuresis in Heart Failure

American Journal of Medicine

Volumn 127, Issue 12, 2014, Pages 1154-1159

  Vaduganathan, Muthiah ^a   Greene, Stephen J ^b   Fonarow, Gregg C ^c   Voors, Adriaan A ^d   Butler, Javed ^e   Gheorghiade, Mihai ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UCLA MEDICAL CENTER   (United States)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

Diuresis; Heart Failure; Readmission

Indexed keywords

NATRIURETIC FACTOR; BIOLOGICAL MARKER; DIURETIC AGENT;

BODY WEIGHT; CARDIAC PATIENT; CLINICAL DECISION MAKING; DISEASE EXACERBATION; DIURESIS; HEART FAILURE; HEMOCONCENTRATION; HEMODYNAMIC MONITORING; HOSPITAL PATIENT; HOSPITAL READMISSION; KIDNEY FUNCTION; MORTALITY; PATIENT MONITORING; POST HOC ANALYSIS; PRACTICE GUIDELINE; PROGNOSIS; RETROSPECTIVE STUDY; REVIEW; BLOOD; BLOOD CELL COUNT; HEMODYNAMICS; HUMAN; WATER-ELECTROLYTE IMBALANCE;

BIOLOGICAL MARKERS; BLOOD CELL COUNT; DIURETICS; HEART FAILURE; HEMODYNAMICS; HUMANS; NATRIURETIC PEPTIDES; PATIENT READMISSION; WATER-ELECTROLYTE IMBALANCE;

EID: 84919683068     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2014.06.009     Document Type: Review

References (43)

1. M. Gheorghiade, M. Vaduganathan, G.C. Fonarow, and R.O. Bonow Rehospitalization for heart failure: problems and perspectives J Am Coll Cardiol 61 2013 391 403
2. K.F. Adams Jr., G.C. Fonarow, and C.L. Emerman Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE) Am Heart J 149 2005 209 216
3. G.C. Fonarow, W.G. Stough, and W.T. Abraham Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry J Am Coll Cardiol 50 2007 768 777
4. H. Bueno, J.S. Ross, and Y. Wang Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure, 1993-2006 JAMA 303 2010 2141 2147
5. K. Dharmarajan, A.F. Hsieh, and Z. Lin Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia JAMA 309 2013 355 363
6. M. Metra, C.M. O'Connor, and B.A. Davison Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study Eur Heart J 32 2011 1519 1534
7. C.M. O'Connor, W.G. Stough, and D.S. Gallup Demographics, clinical characteristics, and outcomes of patients hospitalized for decompensated heart failure: observations from the IMPACT-HF registry J Card Fail 11 2005 200 205
8. M. Vaduganathan, R.O. Bonow, and M. Gheorghiade Thirty-day readmissions: the clock is ticking JAMA 309 2013 345 346
9. B.A. Bart, S.R. Goldsmith, and K.L. Lee Ultrafiltration in decompensated heart failure with cardiorenal syndrome N Engl J Med 367 2012 2296 2304
10. G.M. Felker, and R.J. Mentz Diuretics and ultrafiltration in acute decompensated heart failure J Am Coll Cardiol 59 2012 2145 2153
11. J.L. Januzzi, and R. Troughton Are serial BNP measurements useful in heart failure management? Serial natriuretic peptide measurements are useful in heart failure management Circulation 127 2013 500 508
12. M. Gheorghiade, F. Follath, and P. Ponikowski Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine Eur J Heart Fail 12 2010 423 433
13. J.E. Blair, P.S. Pang, and R.W. Schrier Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial Eur Heart J 32 2011 2563 2572
14. J.E. Blair, S. Khan, and M.A. Konstam Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial Eur Heart J 30 2009 1666 1673
15. R.D. Kociol, S.E. McNulty, and A.F. Hernandez Markers of decongestion, dyspnea relief, and clinical outcomes among patients hospitalized with acute heart failure Circ Heart Fail 6 2013 240 245
16. C.W. Yancy, M. Jessup, and B. Bozkurt 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 62 2013 e147 e239
17. C.S. Wang, J.M. FitzGerald, and M. Schulzer Does this dyspneic patient in the emergency department have congestive heart failure? JAMA 294 2005 1944 1956
18. A.P. Ambrosy, P.S. Pang, and S. Khan Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial Eur Heart J 34 2013 835 843
19. G. Cotter, M. Metra, and O. Milo-Cotter Fluid overload in acute heart failure-re-distribution and other mechanisms beyond fluid accumulation Eur J Heart Fail 10 2008 165 169
20. J.M. Testani, M.A. Brisco, and J.M. Turner Loop diuretic efficiency: a metric of diuretic responsiveness with prognostic importance in acute decompensated heart failure Circ Heart Fail 7 2014 261 270
21. M.A. Valente, A.A. Voors, and K. Damman Diuretic response in acute heart failure: clinical characteristics and prognostic significance Eur Heart J 35 2014 1284 1293
22. C. Binanay, R.M. Califf, and V. Hasselblad Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial JAMA 294 2005 1625 1633
23. A. Bayes-Genis, D. Pascual-Figal, and J. Fabregat Serial NT-proBNP monitoring and outcomes in outpatients with decompensation of heart failure Int J Cardiol 120 2007 338 343
24. P. Bettencourt, A. Azevedo, and J. Pimenta N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients Circulation 110 2004 2168 2174
25. A.J. Singer, R.H. Birkhahn, and D. Guss Rapid Emergency Department Heart Failure Outpatients Trial (REDHOT II): a randomized controlled trial of the effect of serial B-type natriuretic peptide testing on patient management Circ Heart Fail 2 2009 287 293
26. A. Morello, D.M. Lloyd-Jones, and C.U. Chae Association of atrial fibrillation and amino-terminal pro-brain natriuretic peptide concentrations in dyspneic subjects with and without acute heart failure: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study Am Heart J 153 2007 90 97
27. R.D. Kociol, P.S. Pang, and M. Gheorghiade Troponin elevation in heart failure prevalence, mechanisms, and clinical implications J Am Coll Cardiol 56 2010 1071 1078
28. S. Anwaruddin, D.M. Lloyd-Jones, and A. Baggish Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study J Am Coll Cardiol 47 2006 91 97
29. M. Gheorghiade, M. Bohm, and S.J. Greene Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial JAMA 309 2013 1125 1135
30. F. Brandimarte, M. Vaduganathan, and G.F. Mureddu Prognostic implications of renal dysfunction in patients hospitalized with heart failure: data from the last decade of clinical investigations Heart Fail Rev 18 2013 167 176
31. M.M. Givertz, D. Postmus, and H.L. Hillege Renal function trajectories and clinical outcomes in acute heart failure Circ Heart Fail 7 2014 59 67
32. J.M. Testani, B.D. McCauley, and J. Chen Clinical characteristics and outcomes of patients with improvement in renal function during the treatment of decompensated heart failure J Card Fail 17 2011 993 1000
33. J.D. Baillargeon, J. Orav, and V. Ramagopal Hemoconcentration as an early risk factor for necrotizing pancreatitis Am J Gastroenterol 93 1998 2130 2134
34. A. Boyle, and P.A. Sobotka Redefining the therapeutic objective in decompensated heart failure: hemoconcentration as a surrogate for plasma refill rate J Card Fail 12 2006 247 249
35. J.M. Testani, J. Chen, and B.D. McCauley Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival Circulation 122 2010 265 272
36. C. Davila, A. Reyentovich, and S.D. Katz Clinical correlates of hemoconcentration during hospitalization for acute decompensated heart failure J Card Fail 17 2011 1018 1022
37. P. van der Meer, D. Postmus, and P. Ponikowski The predictive value of short-term changes in hemoglobin concentration in patients presenting with acute decompensated heart failure J Am Coll Cardiol 61 2013 1973 1981
38. S.J. Greene, M. Gheorghiade, and M. Vaduganathan Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial Eur J Heart Fail 15 2013 1401 1411
39. J. Oh, S.M. Kang, and N. Hong Hemoconcentration is a good prognostic predictor for clinical outcomes in acute heart failure: data from the Korean Heart Failure (KorHF) Registry Int J Cardiol 168 2013 4739 4743
40. J.M. Testani, M.A. Brisco, and J. Chen Timing of hemoconcentration during treatment of acute decompensated heart failure and subsequent survival: importance of sustained decongestion J Am Coll Cardiol 62 2013 516 524
41. M. Konishi, Y. Matsuzawa, and H. Suzuki Higher level at admission and subsequent decline in hemoglobin in patients with acute pulmonary edema Circ J 78 2014 896 902
42. C. Adlbrecht, S. Kommata, and M. Hulsmann Chronic heart failure leads to an expanded plasma volume and pseudoanaemia, but does not lead to a reduction in the body's red cell volume Eur Heart J 29 2008 2343 2350
43. B. Pitt, and M. Gheorghiade Vasopressin V1 receptor-mediated aldosterone production as a result of selective V2 receptor antagonism: a potential explanation for the failure of tolvaptan to reduce cardiovascular outcomes in the EVEREST trial Eur J Heart Fail 13 2011 1261 1263